Camp4 Therapeutics Corporation
CAMP
$5.41
$0.030.56%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 348.00K | 795.00K | 1.50M | 858.00K | 652.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 348.00K | 795.00K | 1.50M | 858.00K | 652.00K |
| Cost of Revenue | 8.36M | 9.36M | 10.34M | 10.15M | 10.00M |
| Gross Profit | -8.01M | -8.56M | -8.85M | -9.29M | -9.34M |
| SG&A Expenses | 4.77M | 4.60M | 4.18M | 3.81M | 4.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.12M | 13.95M | 14.53M | 13.96M | 14.69M |
| Operating Income | -12.78M | -13.16M | -13.03M | -13.10M | -14.03M |
| Income Before Tax | -40.28M | -15.10M | -12.59M | -12.43M | -13.28M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.28M | -15.10M | -12.59M | -12.43M | -13.28M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.28M | -15.10M | -12.59M | -12.43M | -13.28M |
| EBIT | -12.78M | -13.16M | -13.03M | -13.10M | -14.03M |
| EBITDA | -12.40M | -12.74M | -12.60M | -12.68M | -13.62M |
| EPS Basic | -0.75 | -0.55 | -0.62 | -0.62 | -0.77 |
| Normalized Basic EPS | -0.47 | -0.33 | -0.39 | -0.39 | -0.48 |
| EPS Diluted | -0.75 | -0.55 | -0.62 | -0.62 | -0.77 |
| Normalized Diluted EPS | -0.47 | -0.33 | -0.39 | -0.39 | -0.48 |
| Average Basic Shares Outstanding | 53.86M | 27.27M | 20.16M | 20.15M | 17.25M |
| Average Diluted Shares Outstanding | 53.86M | 27.27M | 20.16M | 20.15M | 17.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |